PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01839487

Recruitment Status : Completed

First Posted : April 25, 2013

Results First Posted : July 20, 2020

Last Update Posted : July 20, 2020

View this study on Beta.ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Halozyme Therapeutics

Study Description

Brief Summary:

This study is designed to compare the treatment effect of PEGPH20 combined with nab-paclitaxel (NAB) and gemcitabine (GEM) [PAG] to NAB and GEM [AG] in participants with Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA).

The study will have 2 run-in phases, one for each formulation of PEGPH20 (original and new formulations), and a Phase 2 portion. The 2 run-in phases will evaluate the safety and tolerability of the PAG treatment using the original and new succinic acid PEGPH20 formulation, respectively, compared with AG treatment. Phase 2 will have 2 stages due to a partial clinical hold that occurred from April through July 2014. The participants will be randomized in 3:1 for the run-in phases. The first stage will randomize participants in a 1:1 ratio. The second stage will randomize participants in a 2:1 ratio (PAG:AG).

This is an open-label study. To minimize bias to the progression-free survival endpoint, disease progression will be based on the assessment of the Central Imaging Reader (CIR). Determination of clinical progression by the Investigator without corresponding CIR confirmation will be documented with the relevant signs and symptoms.

Condition or disease	Intervention/treatment	Phase
Metastatic Pancreatic Cancer	Drug: PEGPH20 Drug: Nab-paclitaxel Drug: Gemcitabine Drug: Dexamethasone Drug: Enoxaparin	Phase 2

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	279 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer
Actual Study Start Date :	May 14, 2013
Actual Primary Completion Date :	May 1, 2018
Actual Study Completion Date :	September 26, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pancreatic Cancer

Drug Information available for: Paclitaxel Gemcitabine Gemcitabine hydrochloride

Genetic and Rare Diseases Information Center resources: Pancreatic Cancer

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Run-in Phase - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine Participants will receive 3.0 micrograms/kilogram (mcg/kg) PEGPH20 with 125 milligrams/square meter (mg/m^2) NAB and 1000 mg/m^2 GEM as intravenous (IV) infusion. In Cycle 1 Week 1, PEGPH20 will be administered alone on Days 1 and 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15 and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1 8 and 15. NAB+GEM will be given 2 to 4 hours after PEGPH20 dose. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior and 8 to 12 hours after completion of each PEGPH20 infusion.	Drug: PEGPH20 PEGPH20 will be administered as per the dose and schedule specified in the respective arms. Drug: Nab-paclitaxel Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms. Other Name: Abraxane Drug: Gemcitabine Gemcitabine will be administered as per the dose and schedule specified in the respective arms. Other Name: Gemzar Drug: Dexamethasone Dexamethasone will be administered as per the dose and schedule specified in the respective arms.
Active Comparator: Run-in Phase - AG: Nab-paclitaxel + Gemcitabine Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM, as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion.	Drug: Nab-paclitaxel Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms. Other Name: Abraxane Drug: Gemcitabine Gemcitabine will be administered as per the dose and schedule specified in the respective arms. Other Name: Gemzar Drug: Dexamethasone Dexamethasone will be administered as per the dose and schedule specified in the respective arms.
Experimental: Phase 2: Stage 1 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine Participants will receive 3.0 mcg/kg PEGPH20 with 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion. In Cycle 1 Week 1, PEGPH20 will be given alone on Days 1 and Day 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15, and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and 15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1, 8, and 15. NAB+GEM will be given 2 to 4 hours after dose of PEGPH20. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning and 8 to 12 hours after the completion of each PEGPH20 infusion.	Drug: PEGPH20 PEGPH20 will be administered as per the dose and schedule specified in the respective arms. Drug: Nab-paclitaxel Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms. Other Name: Abraxane Drug: Gemcitabine Gemcitabine will be administered as per the dose and schedule specified in the respective arms. Other Name: Gemzar Drug: Dexamethasone Dexamethasone will be administered as per the dose and schedule specified in the respective arms.
Active Comparator: Phase 2: Stage 1 - AG: Nab-paclitaxel + Gemcitabine Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion.	Drug: Nab-paclitaxel Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms. Other Name: Abraxane Drug: Gemcitabine Gemcitabine will be administered as per the dose and schedule specified in the respective arms. Other Name: Gemzar Drug: Dexamethasone Dexamethasone will be administered as per the dose and schedule specified in the respective arms.
Experimental: Phase 2: Stage 2 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine Participants will receive 3.0 mcg/kg PEGPH20 with 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion. In Cycle 1 Week 1, PEGPH20 will be given alone on Days 1 and 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15, and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and 15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1, 8, and 15. NAB+GEM will be given 2 to 4 hours after dose of PEGPH20. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to beginning and 8 to 12 hours after completion of each PEGPH20 infusion. Enoxaparin 40 mg/day or 1 mg/kg/day will be given subcutaneously (SC).	Drug: PEGPH20 PEGPH20 will be administered as per the dose and schedule specified in the respective arms. Drug: Nab-paclitaxel Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms. Other Name: Abraxane Drug: Gemcitabine Gemcitabine will be administered as per the dose and schedule specified in the respective arms. Other Name: Gemzar Drug: Dexamethasone Dexamethasone will be administered as per the dose and schedule specified in the respective arms. Drug: Enoxaparin Enoxaparin will be administered as per the dose and schedule specified in the respective arms.
Active Comparator: Phase 2: Stage 2 - AG: Nab-paclitaxel + Gemcitabine Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion. Enoxaparin 40 mg/day or 1 mg/kg/day will be given SC.	Drug: Nab-paclitaxel Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms. Other Name: Abraxane Drug: Gemcitabine Gemcitabine will be administered as per the dose and schedule specified in the respective arms. Other Name: Gemzar Drug: Dexamethasone Dexamethasone will be administered as per the dose and schedule specified in the respective arms. Drug: Enoxaparin Enoxaparin will be administered as per the dose and schedule specified in the respective arms.

Outcome Measures

Primary Outcome Measures :

Progression-Free Survival (PFS) [ Time Frame: From the date of randomization until disease progression or death from any cause (maximum exposure: 30.72 months for PAG, and 20.27 months for AG) ]
PFS: time from randomization until first occurrence of disease progression, either by central radiologic determination (Response Evaluation Criteria in Solid Tumours [RECIST] version 1.1) or by clinical progression determined by Investigator, or death during treatment period from any cause. Radiological disease progression was defined as at least a 20 percent (%) increase in sum of diameters of target lesions, taking as reference the smallest sum on study thus far, nadir (this included baseline sum if that was the smallest on study); Sum must also demonstrate an absolute increase of at least 5 millimeters (mm); Appearance of one or more new lesions; Unequivocal progression of existing non-target lesions. Surviving participants without disease progression were censored for PFS analysis at the date of last evaluable post-baseline tumor assessment. Surviving participants without any post-baseline disease assessment were censored on Day 1. PFS was estimated using Kaplan-Meier (KM) method.
Percentage of Participants in the PAG Arm Who Experienced Any Thromboembolic (TE) Event in Stage 2 of the Study [ Time Frame: From first exposure to any study drug (PEGPH20, NAB, GEM) through 30 days after end of treatment visit (maximum exposure: 30.72 months for PAG) ]
TE events were identified by applying the Medical Dictionary for Regulatory Activities (MedDRA) Standardized MedDRA Queries (SMQ) search strategy for 3 SMQs: TE arterial, TE venous, and TE vessel type unspecified and mixed arterial and venous. TE events were considered by the Sponsor to be adverse events (AEs) of special interest. All TE events, regardless of type of event, severity, or seriousness were reported. Participants with multiple events were counted only once. A summary of serious and all other non-serious adverse events regardless of causality is located in the 'Reported AE section'.

Secondary Outcome Measures :

PFS in Relation to Tumor Hyaluronan (HA) Levels [ Time Frame: From the date of randomization until disease progression or death from any cause (maximum exposure: 30.72 months for PAG, and 20.27 months for AG) ]
PFS was defined as time from randomization until first occurrence of disease progression, either by central radiologic determination (RECIST version 1.1) or by clinical progression determined by Investigator, or death during treatment period from any cause. Disease progression was defined as at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study thus far, nadir (this included baseline sum if that was the smallest on study); Sum must also demonstrate an absolute increase of at least 5 mm; Appearance of one or more new lesions; Unequivocal progression of existing non-target lesions. Surviving participants without disease progression were censored for PFS analysis at the date of last evaluable post-baseline tumor assessment. Surviving participants without any post-baseline disease assessment were censored on Day 1. PFS was estimated using KM method. PFS was measured in HA-high and HA-low participants.
Objective Response Rate (ORR): Percentage of Participants With Objective Response [ Time Frame: From the date of randomization until last date on study treatment (maximum exposure: 30.72 months for PAG, and 20.27 months for AG) ]
ORR was defined as percentage of participants who achieved either a complete response (CR) or partial response (PR) regardless of confirmation, as assessed by RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions; Any pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<) 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Overall Survival [ Time Frame: From randomization until death from any cause (maximum exposure: 30.72 months for PAG, and 20.27 months for AG) ]
Overall survival was defined as the time from randomization until death from any cause. Participants who died or were lost to follow-up by the date of analysis data cutoff were censored at their last contact date.
Percentage of Participants With AEs [ Time Frame: From first exposure to any study drug (PEGPH20, NAB, GEM) through 30 days after end of treatment visit (maximum exposure: 30.72 months for PAG and 20.27 months for AG) ]
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
Maximum Observed Plasma Concentration (Cmax) of PEGPH20 [ Time Frame: Pre-PEGPH20 dosing and 15 minutes, 1 hour, 2 hours, and 4 hours post-PEGPH20 dosing on Days 1 and 15 of Cycle 1 ]
Samples were analyzed for PEGPH20 concentration using a validated electrochemiluminescence immunoassay. Plasma samples to assess the potential effects of NAB+GEM on PEGH20 pharmacokinetic (PK) were collected in the PAG treatment group in the run-in phases (Run-in Phase 1: Original PEGPH20 formulation [3.5 mg/mL], and Run-in Phase 2: New PEGPH20 formulation [0.3 mg/mL]).
Time to Reach Cmax (Tmax) of PEGPH20 [ Time Frame: Pre-PEGPH20 dosing and 15 minutes, 1 hour, 2 hours, and 4 hours post-PEGPH20 dosing on Days 1 and 15 of Cycle 1 ]
Samples were analyzed for PEGPH20 concentration using a validated electrochemiluminescence immunoassay. Plasma samples to assess the potential effects of NAB+GEM on PEGH20 PK were collected in the PAG treatment group in the run-in phases (Run-in Phase 1: Original PEGPH20 formulation [3.5 mg/mL], and Run-in Phase 2: New PEGPH20 formulation [0.3 mg/mL]).
Area Under the Concentration-Time Curve From Time 0 to Last Quantifiable Concentration (AUC0-last) of PEGPH20 [ Time Frame: Pre-PEGPH20 dosing and 15 minutes, 1 hour, 2 hours, and 4 hours post-PEGPH20 dosing on Days 1 and 15 of Cycle 1 ]
Samples were analyzed for PEGPH20 concentration using a validated electrochemiluminescence immunoassay. Plasma samples to assess the potential effects of NAB+GEM on PEGH20 PK were collected in the PAG treatment group in the run-in phases (Run-in Phase 1: Original PEGPH20 formulation [3.5 mg/mL], and Run-in Phase 2: New PEGPH20 formulation [0.3 mg/mL]).

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Key Inclusion Criteria:

Signed Informed consent.
Histologically confirmed Stage IV PDA with documented disseminated neoplasm to liver and /or lung. Must have archival or fresh tissue (block /slides) available pre-dose.
One or more metastatic tumors measurable on computed tomography (CT) scan per RECIST v.1.1 , excluding the primary pancreatic lesion.
No previous radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease.
Karnofsky Performance Status greater than or equal to (≥) 70%.
Life expectancy ≥3 months.
Age ≥18 years.
Screening laboratory values of hemoglobin, platelets, absolute neutrophil count (ANC), bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum creatinine, serum albumin, prothrombin time/international normalized ratio (INR), and partial thromboplastin time (PTT) within specified values/criteria per protocol prior to dosing.

Key Exclusion Criteria:

Non-metastatic PDA.
Evidence of deep vein thrombosis (DVT), pulmonary embolism (PE), or other known thromboembolic event present during screening period.
Known central nervous system involvement or brain metastasis.
New York (NY) Heart Association Class III or IV cardiac disease or myocardial infarction within the past 12 months.
Prior history of cerebrovascular accident or transient ischemic attack.
Pre-existing carotid artery disease.
Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy.
Current use of megestrol acetate (use within 10 days of Day 1).
Known infection with human immunodeficiency virus, Hepatitis B, or Hepatitis C.
History of another primary cancer within the last 3 years with the exception of non-melanoma skin cancer, early state prostate cancer, or curatively-treated cervical cancer in-situ.
Contraindication to heparin as per National Comprehensive Cancer Network (NCCN) guidelines.
Previous major bleed (bleeding requiring transfusion of red blood cells) on low-molecular weight heparin (LMWH).
Any other disease, metabolic dysfunction, physical examination finding or clinical laboratory finding that leads to reasonable suspicion of disease or condition that contraindicates the use of an investigational drug, that may affect interpretation of results, or render the participant at a high risk of treatment complications.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01839487

Locations

Show 51 study locations

Layout table for location information

United States, Alabama
Alabama Oncology
Birmingham, Alabama, United States, 35213
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States, 36604
United States, Arizona
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States, 85234
Mayo Clinic - Scottsdale
Scottsdale, Arizona, United States, 85259
Arizona Oncology Associates, PC
Tucson, Arizona, United States, 85704
United States, Arkansas
Highlands Oncology Group
Fayetteville, Arkansas, United States, 72703
United States, California
Providence St Joseph Medical Center
Burbank, California, United States, 91505
Scripps Cancer Center
La Jolla, California, United States, 92037
UCSD - Moore's Cancer Center
La Jolla, California, United States, 92093
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
University of California Medical Center
Orange, California, United States, 92868
Saint Helena Hospital
Saint Helena, California, United States, 94574
Pacific Hematology Oncology Associates
San Francisco, California, United States, 94115
The Oncology Institute of Hope and Innovation
Whittier, California, United States, 90603
United States, Colorado
University of Colorado Cancer Center
Aurora, Colorado, United States, 80045
Rocky Mountain Cancer Center
Denver, Colorado, United States, 80218
United States, Connecticut
Stamford Hospital
Stamford, Connecticut, United States, 06902
United States, District of Columbia
Georgetown University Medical Center
Washington, District of Columbia, United States, 20007
United States, Florida
University of Miami, Sylvester comprehensive Cancer Center
Miami, Florida, United States, 33136
H. Lee Moffit Cancer Center
Tampa, Florida, United States, 33612
United States, Georgia
Piedmont Hospital
Atlanta, Georgia, United States, 30318
United States, Illinois
Loyola University Medical Center
Maywood, Illinois, United States, 60153
United States, Kentucky
Norton Cancer Institute - Norton HealthCare Pavilion
Louisville, Kentucky, United States, 40202
United States, Maryland
Johns Hopkins University Hospital
Baltimore, Maryland, United States, 21231
United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Lahey Clinic
Burlington, Massachusetts, United States, 01805
University of Mass Medical School
Worcester, Massachusetts, United States, 01655
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
United States, Minnesota
Virginia Piper Cancer Institute
Minneapolis, Minnesota, United States, 55407
Unniversity of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Research Medical Center
Kansas City, Missouri, United States, 64132
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, Nevada
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States, 89169
United States, New Jersey
St. Joseph's Regional Medical Center
Paterson, New Jersey, United States, 07503
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
North Shore Long Island Jewish Health System
Lake Success, New York, United States, 11042
Mount Sinai Medical Center
New York, New York, United States, 10029
Columbia University Medical Center
New York, New York, United States, 10032
University of Rochester
Rochester, New York, United States, 14642
United States, Ohio
Gabrail Cancer Center
Canton, Ohio, United States, 44718
United States, Oklahoma
University of Oklahoma Health Science Center
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
UPMC Cancer Center
Pittsburgh, Pennsylvania, United States, 15213
United States, South Carolina
Greenville Health System
Greenville, South Carolina, United States, 29605
United States, Texas
Texas Oncology - Baylor
Dallas, Texas, United States, 75246
Cancer Care Centers of South Texas
New Braunfels, Texas, United States, 78130
Texas Oncology
Tyler, Texas, United States, 75702
United States, Washington
Columbia Basin Hematology and Oncology
Kennewick, Washington, United States, 99336
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109
NorthWest Medical Specialties, PLLC
Tacoma, Washington, United States, 98405
United States, Wisconsin
University of Wisconsin Hospitals and Clinics
Madison, Wisconsin, United States, 53792
Froedtert Hospital, Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226

Sponsors and Collaborators

Halozyme Therapeutics

Investigators

Layout table for investigator information

Study Director:	VP, Clinical Development	Halozyme Therapeutics

Study Documents (Full-Text)

Documents provided by Halozyme Therapeutics:

Study Protocol [PDF] February 9, 2018

Statistical Analysis Plan [PDF] December 12, 2016

More Information

Additional Information:

Reflects interim analysis conducted on mature data when 95% of participants had discontinued from the study. This link exits the ClinicalTrials.gov site

This link exits the ClinicalTrials.gov site

Publications of Results:

Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, Hendifar AE. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. J Clin Oncol. 2018 Feb 1;36(4):359-366. doi: 10.1200/JCO.2017.74.9564. Epub 2017 Dec 12.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Wang S, Bager CL, Karsdal MA, Chondros D, Taverna D, Willumsen N. Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa. J Transl Med. 2021 Jan 21;19(1):39. doi: 10.1186/s12967-021-02701-z.

Layout table for additonal information

Responsible Party:	Halozyme Therapeutics
ClinicalTrials.gov Identifier:	NCT01839487
Other Study ID Numbers:	HALO-109-202
First Posted:	April 25, 2013 Key Record Dates
Results First Posted:	July 20, 2020
Last Update Posted:	July 20, 2020
Last Verified:	July 2020

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	Yes
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Halozyme Therapeutics:


pancreatic ductal carcinoma(PDA) Pancreatic ductal carcinoma PEGPH20 Gemcitabine Nab-paclitaxel

Additional relevant MeSH terms:

Layout table for MeSH terms

Pancreatic Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases Dexamethasone Paclitaxel Gemcitabine Enoxaparin Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators	Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antimetabolites, Antineoplastic Antimetabolites

To Top